Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

被引：186

作者：

Tanizaki, Junko ^{[1
]}

Haratani, Koji ^{[1
]}

Hayashi, Hidetoshi ^{[1
]}

Chiba, Yasutaka ^{[2
]}

Nakamura, Yasushi ^{[3
]}

Yonesaka, Kimio ^{[1
]}

Kudo, Keita ^{[4
,5
]}

Kaneda, Hiroyasu ^{[1
,6
]}

Hasegawa, Yoshikazu ^{[7
]}

Tanaka, Kaoru ^{[1
]}

Takeda, Masayuki ^{[1
]}

Ito, Akihiko ^{[3
]}

Nakagawa, Kazuhiko ^{[1
]}

机构：

[1] Kindai Univ, Dept Med Oncol, Fac Med, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan

[2] Kindai Univ Hosp, Clin Res Ctr, Osaka, Japan

[3] Kindai Univ, Dept Pathol, Fac Med, Osaka, Japan

[4] Natl Hosp Org, Osaka Minami Med Ctr, Dept Med Oncol, Kawachi Nagano, Japan

[5] Natl Hosp Org, Osaka Minami Med Ctr, Dept Resp Med, Kawachi Nagano, Japan

[6] Kishiwada City Hosp, Dept Med Oncol, Kishiwada, Japan

[7] Izumi Municipal Hosp, Dept Med Oncol, Izumi, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 01期

关键词：

Non-small cell lung cancer; Nivolumab; Peripheral blood biomarker; Prognostic factor; Predictive factor; METASTATIC MELANOMA PATIENTS; TO-LYMPHOCYTE RATIO; STAGE-IV; IPILIMUMAB; SURVIVAL; EOSINOPHILS; NEUTROPHILS; TUMORS; EXPERIENCE; DOCETAXEL;

D O I：

10.1016/j.jtho.2017.10.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. Methods: Univariable and multivariable analyses were performed retrospectively for 134 patients with advanced or recurrent NSCLC treated with nivolumab to evaluate the relationship between survival and peripheral blood parameters measured before treatment initiation, including absblute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count, and absolute eosinophil count (AEC), as well as serum C-reactive protein and lactate dehydrogenase levels. Progression-free survival, overall survival, and response rate were determined. Results: Among the variables selected by univariable analysis, a low ANC, high ALC, and high AEC were significantly and independently associated with both better progression-free survival (p = 0.001, p = 0.04, and p = 0.02, respectively) and better overall survival (p = 0.03, p = 0.03, and p = 0.003, respectively) in multivariable analysis. Categorization of patients according to the number of favorable factors revealed that those with only one factor had a significantly worse outcome than those with two or three factors. A similar trend was apparent for patients with a programmed death 1 ligand tumor proportion score less than 50%, whereas all patients with a score of 50% or higher had at least two favorable factors. Conclusions: A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：97 / 105

页数：9

共 26 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[4] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[5] Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells [J].

Carretero, Rafael ;

Sektioglu, Ibrahim M. ;

Garbi, Natalio ;

Salgado, Oscar C. ;

Beckhove, Philipp ;

Haemmerling, Guenter J. .

NATURE IMMUNOLOGY, 2015, 16 (06) :609-+

[6] Eosinophils and Cancer [J].

Davis, Benjamin P. ;

Rothenberg, Marc E. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (01) :1-8

[7] Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival [J].

Delyon, J. ;

Mateus, C. ;

Lefeuvre, D. ;

Lanoy, E. ;

Zitvogel, L. ;

Chaput, N. ;

Roy, S. ;

Eggermont, A. M. M. ;

Routier, E. ;

Robert, C. .

ANNALS OF ONCOLOGY, 2013, 24 (06) :1697-1703

[8] Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer [J].

Derman, B. A. ;

Macklis, J. N. ;

Azeem, M. S. ;

Sayidine, S. ;

Basu, S. ;

Batus, M. ;

Esmail, F. ;

Borgia, J. A. ;

Bonomi, P. ;

Fidler, M. J. .

BMC CANCER, 2017, 17

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J].

Ferrucci, P. F. ;

Ascierto, P. A. ;

Pigozzo, J. ;

Del Vecchio, M. ;

Maio, M. ;

Cappellini, G. C. Antonini ;

Guidoboni, M. ;

Queirolo, P. ;

Savoia, P. ;

Mandala, M. ;

Simeone, E. ;

Valpione, S. ;

Altomonte, M. ;

Spagnolo, F. ;

Cocorocchio, E. ;

Gandini, S. ;

Giannarelli, D. ;

Martinoli, C. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :732-738

← 1 2 3 →